

54113.8004.US01

AMENDMENT OF THE CLAIMS

1-25. (Cancelled)

26. (Previously Amended) A method for improving the efficiency of *in vivo* liver cell retroviral transduction, the method comprising, inducing a semi-synchronous wave of *in vivo* liver cell proliferation by concurrently administering tri-iodothyronine (T3) and keratinocyte growth factor (KGF), and further comprising administering to the liver a retroviral vector complexed with cationic liposomes subsequent to the induction of liver cell proliferation, thereby increasing transduction efficiency.

27. (Previously Added) The method of claim 26, the cationic liposome comprising DiOctadecylamidoGlycylSpermine (DOGS).

28-50. (Cancelled)

51. (Presently Amended) A method for treating ~~or preventing~~ cirrhosis of the liver comprising concurrently administering to a subject an effective amount of T3 and an effective amount of KGF, thereby inducing a semi-synchronous wave of liver cell proliferation *in vivo*, and further comprising administering to a liver cell a retroviral vector complexed with cationic liposomes wherein the retroviral vector encodes hepatocyte growth factor (HGF), which treats ~~or~~ prevents cirrhosis of the liver.

52. (Currently Amended) The method of claim 51, wherein the effective amount of T3 ranges ~~is ranging~~ from about 400 μ g per kg of body weight of the subject to about 40 mg per kg of body weight of the subject.

53. (Previously Added) The method of claim 52, wherein the effective amount of T3 is about 4 mg per kg of body weight of the subject.

54113.8004.US01

54. (Currently Amended) The method of claim 51, wherein the effective amount of KGF ranges is ranging from about 100 μ g per kg of body weight of the subject to about 10 mg per kg of body weight of the subject.

55. (Previously Added) The method of claim 54, wherein the effective amount of KGF is about 1 mg per kg of body weight of the subject.

56. (Presently Amended) The method of claim 51, wherein the effective amount of T3 and the effective amount of KGF is in a weight ratio of about 4:1.

57. (Previously Added) The method of claim 56, wherein the effective amount of T3 is in a dose of about 4 mg per kg of body weight of the subject and the effective amount of KGF is in a dose of about 1 mg per kg of body weight of the subject.

58. (Previously Added) The method of claim 57, wherein the composition is administered subcutaneously.

59. (Previously Added) The method of claim 57, wherein the composition is administered intravenously.

60. (Previously Added) The method of claim 57, wherein the composition is administered intramuscularly.

61. (Previously Added) The method of claim 57, wherein the composition is administered intraperitoneally.

62. (Previously Added) The method of claim 57, wherein the composition is administered directly into the liver.

63. (Previously Added) The method of claim 51, the cationic liposome comprising DiOctadecylamidoGlycylSpermine (DOGS).

54113.8004.US01

64. (Previously Added) The method of claim 51, wherein the retroviral vector is administered between about 6 hours and 14 days after administration of the composition.

65. (Previously Added) The method of claim 51, wherein the retroviral vector is administered between about 24 hours and 8 days after administration of the composition.

66. (New) A method for treating a subject at risk of developing cirrhosis of the liver comprising concurrently administering to a subject an effective amount of T3 and an effective amount of KGF, thereby inducing a semi-synchronous wave of liver cell proliferation *in vivo*, and further comprising administering to a liver cell a retroviral vector complexed with cationic liposomes wherein the retroviral vector encodes hepatocyte growth factor, which treats the risk of developing cirrhosis of the liver.

67. (New) The method of claim 66, wherein the effective amount of T3 ranges from about 400 µg per kg of body weight of the subject to about 40 mg per kg of body weight of the subject, and the effective amount of KGF ranges from about 100 µg per kg of body weight of the subject to about 10 mg per kg of body weight of the subject.

68. (New) The method of claim 66, wherein the composition is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, or directly into the liver, and wherein the cationic liposome comprises DiOctadecylamidoGlycylSpermine.